DBV Technologies
Clinical trials sponsored by DBV Technologies, explained in plain language.
DBV Technologies
DBVT
NASDAQ
A biopharmaceutical company focused on food allergy treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Peanut patch for toddlers: could a sticker ease allergy fears? Results expected Nov 2026 (estimated) 🚀 Make-or-break